A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, Yoshikawa J; POPPS Investigators.
Takagi T, et al. Among authors: yoshikawa j.
JACC Cardiovasc Interv. 2009 Jun;2(6):524-31. doi: 10.1016/j.jcin.2009.04.007.
JACC Cardiovasc Interv. 2009.
PMID: 19539256
Free article.
Clinical Trial.